CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Cao, Rui, Evan Olawsky, Edward McFowland III, Erin Marcotte, Logan Spector, and Tianzhong Yang. "Subset Scanning for Multi-Trait Analysis Using GWAS Summary Statistics." Bioinformatics 40, no. 1 ...
GASC1 expression to predict response to paclitaxel plus cisplatin in oesophageal squamous cell carcinoma. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not ...
Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non–Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma ...
Zovegalisib is currently being evaluated in ReDiscover, an ongoing first-in-human study, which was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary ...
Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback